Cargando…

Surgical series in mesothelioma: navigating between biases

Detalles Bibliográficos
Autores principales:	Raskin, Jo, Van Schil, Paul E., Meerbeeck, Jan P. Van
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989814/ https://www.ncbi.nlm.nih.gov/pubmed/36895921 http://dx.doi.org/10.21037/tlcr-23-34

Ejemplares similares

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma
por: Rovers, Sophie, et al.
Publicado: (2022)

External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma
por: Janssens, Eline, et al.
Publicado: (2022)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Investigational Approaches for Mesothelioma
por: Surmont, Veerle F., et al.
Publicado: (2011)

Mesothelioma treatment: Are we on target? A review
por: Hiddinga, Birgitta I., et al.
Publicado: (2015)

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis
por: Schillebeeckx, Eline, et al.
Publicado: (2021)

Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
por: Lagniau, Sabrina, et al.
Publicado: (2017)

Lung Cancer Screening: New Perspective and Challenges in Europe
por: Van Meerbeeck, Jan P., et al.
Publicado: (2022)

Recent developments in the treatment of small cell lung cancer
por: Hiddinga, Birgitta I., et al.
Publicado: (2021)

Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2023)

Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges
por: Diebels, Ian, et al.
Publicado: (2022)

Spare the lung: surgical treatment approach for malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2023)

Evaluation of the solitary pulmonary nodule: size matters, but do not ignore the power of morphology
por: Snoeckx, Annemie, et al.
Publicado: (2017)

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
por: Marcq, Elly, et al.
Publicado: (2019)

Cancer in the time of COVID-19: expert opinion on how to adapt current practice
por: Raskin, Jo, et al.
Publicado: (2020)

Mesothelioma
por: Deraco, Marcello
Publicado: (2021)

Sublobar Resection for Early-Stage Lung Cancer: An Oncologically Valid Procedure?
por: Diebels, Ian, et al.
Publicado: (2023)

Malignant Mesothelioma
por: Pouliquen, Daniel L., et al.
Publicado: (2021)

Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study
por: Lamote, Kevin, et al.
Publicado: (2017)

Lung cancer screening: the preface
por: Snoeckx, Annemiek, et al.
Publicado: (2021)

Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma
por: Hylebos, Marieke, et al.
Publicado: (2017)

New Implications of Patients’ Sex in Today’s Lung Cancer Management
por: Raskin, Jo, et al.
Publicado: (2022)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
por: van Meerbeeck, J., et al.
Publicado: (1996)

Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research
por: Janssens, Eline, et al.
Publicado: (2022)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Excluded futures: the continuity bias in scenario assessments
por: Raskin, Paul, et al.
Publicado: (2020)

Asbestos, mesothelioma and the legacy of shipbuilding in Belfast
por: Morrison, Patrick J
Publicado: (2008)

Supplementary Prognostic Variables for Pleural Mesothelioma: A Report from the IASLC Staging Committee
por: Pass, Harvey I., et al.
Publicado: (2014)

Spatial navigation, aging and Alzheimer’s disease
por: Laczó, Jan, et al.
Publicado: (2018)

The interpretation bias and trap of multicenter clinical research
por: Jo, Daehyun
Publicado: (2020)

Malignant Pleural Mesothelioma: Time Is Running Out
por: Lococo, Filippo
Publicado: (2021)

Malignant mesothelioma: health care awareness and preparedness
por: Capitani, Eduardo Mello De, et al.
Publicado: (2022)

The story of the pandemic: navigating our way between optimism and pessimism
por: Unrau, Rona
Publicado: (2020)

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach
por: Popat, Sanjay, et al.
Publicado: (2020)

The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma
por: Wheatley-Price, Paul, et al.
Publicado: (2022)

Surgical navigation in paediatric orthopaedics
por: Docquier, Pierre-Louis, et al.
Publicado: (2016)

Bias and the Evidence ‘Biased’ Medicine
por: Shyam, Ashok
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tg1qb0h6o8accpkkdgnvvjmrlh